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Letter to the Editor
We are grateful to Basaran et al1 for their relevant 
comments.
We agree that “much effort is needed for selection of 
inappropriateness criteria.” In our study, appropriateness cri-
teria were defined after a review of the literature in the field, 
including original research articles, systematic reviews/
meta-analyses, and clinical guidelines. However, data or rec-
ommendations were either divergent or lacking for some 
important criteria (eg, first choice of oral anticoagulant, clin-
ical relevance of some drug interactions, switch of direct 
oral anticoagulants [DOACs] in case of renal insufficiency). 
In addition, discrepancies in the definition of nonvalvular 
atrial fibrillation (NVAF) were observed between large 
phase III trials. In light of these limitations, we defined 
appropriateness according to available evidence and expert 
opinion.
Because of the lack of consensus in the definition of 
NVAF, we decided to use the broadest definition used in the 
RE-LY study.2 We considered the indication as inappropri-
ate in the following situations: patients with severe aortic or 
mitral insufficiency, severe aortic or mitral stenosis, or with 
a prosthetic valve. In line with the recent American and 
European guidelines, aortic stenosis could have been 
excluded from this list. In our study, only 2 out of the 8 
patients had an inappropriate indication resulting from 
severe aortic stenosis. If we consider them as appropriate, 
the prevalence of inappropriate indication would change 
from 12% to 9%. Therefore, the impact of this sensitivity 
analysis on the overall conclusion remains limited.
In response to the second comment, based on current 
recommendations of the European Society of Cardiology, 
we considered as an appropriate indication a patient with 
NVAF and a CHA
2
DS
2
VASc score ≥1, except for the situa-
tion of female patients with gender alone as a single risk 
factor (because they do not need anticoagulation if they 
clearly fulfill the criteria of age <65 years and lone AF).3 In 
our study, no patient had a CHA
2
DS
2
VASc score of 0, 3 
patients had a score of 1 (one being a woman <65 years and 
with lone AF), and all other patients (n = 66) had a score ≥1.
Regarding the last comment, we agree that there is no 
international consensus on switching from one DOAC to 
another because of renal insufficiency, but recommendations 
were proposed by scientific associations.4 In our study, only 
1 out of the 3 inappropriate ratings for the “choice” criterion 
was related to renal function. This patient had moderate 
renal impairment, failed to be well controlled with a vitamin 
K antagonist, and was receiving dabigatran etexilate (DE) at 
the time of the study. We considered rivaroxaban to be more 
appropriate because rivaroxaban is less affected by impaired 
renal function than DE.4 The 2 other patients with an inap-
propriate rating had swallowing problems and were receiv-
ing DE. We considered DE as inappropriate because crushing 
of the tablet is only allowed for rivaroxaban.
In conclusion, in the absence of international consensus, 
choices were made to identify the best criteria for appropri-
ate use of DOACs. Sensitivity analysis using modified cri-
teria support the conclusion that inappropriate use of DE 
and rivaroxaban in patients with NVAF is frequent.
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